Trial · NCT00566995
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response Rate. | Vandetanib in Participants With Kidney Cancer | Partial Response | 3 | percentage of participants | |
| Overall Response Rate. | Vandetanib in Participants With Kidney Cancer | Complete Response | 0 | percentage of participants | |
| Overall Response Rate. | Vandetanib in Participants With Kidney Cancer | Stable Disease | 75 | percentage of participants | |
| Overall Response Rate. | Vandetanib in Participants With Kidney Cancer | Progressive Disease | 0 | percentage of participants | |
| Overall Response Rate. | Vandetanib in Participants With Kidney Cancer | Not Evaluable | 22 | percentage of participants | |
| Number of Participants With Adverse Events | Vandetanib in Participants With Kidney Cancer | 37 | Participants | ||
| Time To Progression (TTP) | Vandetanib in Participants With Kidney Cancer | 13.8 | 95% Confidence Interval 11.0 to 22.1 | Months | |
| Progression Free Survival (PFS) | Vandetanib in Participants With Kidney Cancer | 13.8 | 95% Confidence Interval 11.0 to 22.1 | Months | |
| Effect of Vandetanib (ZD6474) on Endothelial Progenitor Cells | Vandetanib in Participants With Kidney Cancer | Cycle 1 Day 1 Pre treatment | 214.44 | Full Range 0 to 906.7 | Cells per 10^6 mononuclear cells |
| Effect of Vandetanib (ZD6474) on Endothelial Progenitor Cells | Vandetanib in Participants With Kidney Cancer | Cycle 1 Day 1, 4 hours post | 115.79 | Full Range 0 to 282.69 | Cells per 10^6 mononuclear cells |
| Effect of Vandetanib (ZD6474) on Endothelial Progenitor Cells | Vandetanib in Participants With Kidney Cancer | Cycle 2 Day 1 | 160.20 | Full Range 0 to 640.6 | Cells per 10^6 mononuclear cells |
| Effect of Vandetanib (ZD6474) on Circulating Endothelial Cells (CEC) | Vandetanib in Participants With Kidney Cancer | Cycle 1 day 1 Pre treatment | 83.83 | Full Range 0 to 314.20 | CEC per 10^6 mononuclear cells |
| Effect of Vandetanib (ZD6474) on Circulating Endothelial Cells (CEC) | Vandetanib in Participants With Kidney Cancer | Cycle 1 Day 1, 4 hours post | 63.08 | Full Range 0 to 307.40 | CEC per 10^6 mononuclear cells |
| Effect of Vandetanib (ZD6474) on Circulating Endothelial Cells (CEC) | Vandetanib in Participants With Kidney Cancer | Cycle 2 Day 1 | 155.8 | Full Range 0 to 2480 | CEC per 10^6 mononuclear cells |
| Response in Pancreatic Tumors/Cysts Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Complete Response | 0 | Participants | |
| Response in Pancreatic Tumors/Cysts Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Partial Response | 0 | Participants | |
| Response in Pancreatic Tumors/Cysts Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Progressive Disease | 0 | Participants | |
| Response in Pancreatic Tumors/Cysts Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Stable Disease | 2 | Participants | |
| Response in Central Nervous System (CNS) Hemangioblastomas Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Complete Response | 0 | Participants | |
| Response in Central Nervous System (CNS) Hemangioblastomas Associated With Von Hippel Lindau (VHL) | Vandetanib in Participants With Kidney Cancer | Partial Response | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00566995/results